Trial Profile
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesetaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Genta (CEASED)
- 12 Jun 2018 Status changed from active, no longer recruiting to completed, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results (n=38) assessing efficacy of tesetaxel in women with locally advanced or metastatic HER2-negative breast cancer who had not previously received chemotherapy, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2018 Results from patients with HER2 negative, HR positive Metastatic Breast Cancer (n=38) published in an Odonate Therapeutics Media Release